Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

O. Gottardi; F. Scanzi; S. Zurrida; A. Bono; M. Majno; P. Colombo; M. Ferrari; M. Gambacocta; N. Rossi

doi:10.1016/0960-9776(93)90034-D

Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

O. Gottardi, F. Scanzi, S. Zurrida, A. Bono, M. Majno, P. Colombo, M. Ferrari, M. Gambacocta, N. Rossi

Research output: Contribution to journal › Article › peer-review

Abstract

The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

Original language	English
Pages (from-to)	33-36
Number of pages	4
Journal	Breast
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/0960-9776(93)90034-D
Publication status	Published - 1993

ASJC Scopus subject areas

Obstetrics and Gynaecology

Access to Document

10.1016/0960-9776(93)90034-D

Cite this

@article{8c70d036f8bd48bc948037b5b9e0f4e7,

title = "Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer",

abstract = "The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.",

author = "O. Gottardi and F. Scanzi and S. Zurrida and A. Bono and M. Majno and P. Colombo and M. Ferrari and M. Gambacocta and N. Rossi",

year = "1993",

doi = "10.1016/0960-9776(93)90034-D",

language = "English",

volume = "2",

pages = "33--36",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "1",

}

TY - JOUR

T1 - Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

AU - Gottardi, O.

AU - Scanzi, F.

AU - Zurrida, S.

AU - Bono, A.

AU - Majno, M.

AU - Colombo, P.

AU - Ferrari, M.

AU - Gambacocta, M.

AU - Rossi, N.

PY - 1993

Y1 - 1993

N2 - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

AB - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

UR - http://www.scopus.com/inward/record.url?scp=0027256591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027256591&partnerID=8YFLogxK

U2 - 10.1016/0960-9776(93)90034-D

DO - 10.1016/0960-9776(93)90034-D

M3 - Article

AN - SCOPUS:0027256591

VL - 2

SP - 33

EP - 36

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -

Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this